GiveWell started supporting vaccines in 2015 and has made over $160 million in grants to date. With strong results from past work in this space, we’re now exploring how to reach more people with vaccines in low- and middle-income countries. This post discusses our current thinking on vaccines grantmaking and our key hypotheses about where to focus our efforts going forward.
Where are we now?
Before this year, our grants for vaccine programs focused on (a) increasing uptake of the vaccines given to children in the first two years of life, and (b) speeding up the rollout of malaria vaccines.
Relative to other global health approaches, vaccines garner a lot of attention. Governments in high-income countries contribute to Gavi, the Vaccine Alliance, which heavily subsidizes the purchasing of vaccines in the world’s poorest countries and provides cash assistance to help these countries deliver them. The Gates Foundation is also a major contributor to vaccine programs. These efforts have been fairly successful—in 2022, 81% of children in the 57 low-income countries supported by Gavi had received the DTP3 vaccine, which protects against diphtheria, tetanus, and pertussis. DTP3 coverage is often used as a benchmark for progress on vaccination.
This provides both a challenge and an opportunity for finding cost-effective giving opportunities. On the one hand, thankfully, the people who are easiest to reach with vaccines are already being reached, which means more expensive or innovative methods are needed to expand coverage. On the other hand, we can build on the extensive knowledge and infrastructure that already exists.